newsfilter
← Latest News
GlobeNewswire·

Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results

– Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment